Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review

BMC Pediatrics

Table 4 Summary of mucosal healing rate among patients with Crohn’s disease or Ulcerative Colitis receiving vedolizumab

IBD type	Study	Patients with mucosal healing (n)	Patients assessed (n)	Rate (%)	Follow-up time(weeks):Median[IQR]
CD
	Ledder (2017) [24]	1	6	17	24[14–38]
	Jossen (2020) [27]	13	33	39	49[32–73]
UC/IBD-U
	Ledder (2017) [24]	2	13	15	24[14–36]
	Jossen (2020) [27]	12	35	34	49[32–73]

Abbreviations: IBD, inflammatory bowel disease, CD Crohn’s disease, UC ulcerative disease, IBD-U inflammatory bowel disease unspecified

ISSN: 1471-2431